Tandem Diabetes Care Inc (OQ:TNDM)

Business Focus: Medical Equipment, Supplies & Distribution

Nov 08, 2019 04:05 pm ET
Tandem Diabetes Care Announces Upcoming Conference Presentations
Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will be attending the following upcoming investor conferences:
Nov 04, 2019 04:05 pm ET
Tandem Diabetes Care Announces Third Quarter 2019 Financial Results and Updated 2019 Financial Guidance
Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today reported its financial results for the quarter ended September 30, 2019 and updated its financial guidance for the year ending December 31, 2019.
Nov 01, 2019 04:15 pm ET
2019 Beyond Type Run Team to Race the TCS New York City Marathon Using Basal-IQ Technology from Tandem Diabetes Care
Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, is supporting the efforts of Beyond Type 1, a global diabetes advocacy organization, in fielding its largest marathon team in history, made up of 30 runners with a combined 385 years of experience living with type 1 diabetes. The Beyond Type Run team will be running the TCS New York City Marathon on November 3, 2019, and Tandem Diabetes Care has made the t:slim X2™ insulin pump with Basal-IQ® technology available to all team members. A majority of the team chose to use the system for their pe
Oct 30, 2019 04:05 pm ET
Tandem Diabetes Care Presents Positive Real-World Data from Pediatric Users of t:slim X2 Insulin Pump with Basal-IQ Technology at International Conference
Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced presentation of real-world data from pediatric users of the t:slim X2™ insulin pump with Basal-IQ® predictive low-glucose suspend technology at the 45th annual conference of the International Society for Pediatric and Adolescent Diabetes (ISPAD). Data from 2,696 users under the age of 18 years old showed an overall rate of hypoglycemia of only 0.9 percent when using Basal-IQ technology. A subgroup of users with at least 21 days of sensor-augmented pump data prior to
Oct 16, 2019 05:15 pm ET
Tandem Diabetes Care Announces NEJM Publication of Landmark Study Demonstrating Increased Time-In-Range with the t:slim X2 Insulin Pump with Control-IQ Technology
Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced publication by the New England Journal of Medicine (NEJM) of results from the landmark Protocol 3 study (DCLP3) of the National Institutes of Health (NIH)-funded International Diabetes Closed Loop (iDCL) trial using the t:slim X2™ insulin pump with Control-IQ™ advanced hybrid closed-loop technology. The DCLP3 study was the first-ever large-scale, six-month closed-loop study that included a dedicated control group. Over the six-month study period, use of Control-IQ techn
Oct 15, 2019 08:00 am ET
Abbott and Tandem Diabetes Care Exploring New Integrated Solutions to Improve Diabetes Management
ABBOTT PARK, Ill. and SAN DIEGO, Oct. 15, 2019 /PRNewswire/ -- Abbott (NYSE: ABT) and Tandem Diabetes Care (NASDAQ: TNDM) announced today that they intend to develop and commercialize integrated diabetes solutions that combine Abbott's world-leading1 glucose sensing technology with Tandem's innovative insulin delivery systems to provide more options for people to manage their diabetes.  ...
Oct 14, 2019 04:05 pm ET
Tandem Diabetes Care to Announce Third Quarter 2019 Financial Results on November 4, 2019
Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its third quarter 2019 results after the financial markets close on Monday, November 4, 2019. The Company will hold a conference call and simultaneous webcast on the same day at 4:30pm Eastern Time (1:30pm Pacific Time), to discuss its third quarter 2019 financial and operating results.
Sep 18, 2019 04:15 pm ET
Tandem Diabetes Care Announces Publication of Real-world Basal-IQ Predictive Low Glucose Suspend Technology Data in Diabetes Technology and Therapeutics Journal
Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced publication of real-world data from more than 8,000 users of the t:slim X2™ insulin pump with Basal-IQ® predictive low-glucose suspend technology in the medical journal Diabetes Technology and Therapeutics. The results demonstrate sustained reductions in hypoglycemia across all groups using Basal-IQ technology, regardless of prior therapy. A specific sub-analysis of t:slim X2 pump users who remotely updated their pump software to Basal-IQ technology revealed a 45 percen
Aug 29, 2019 04:30 pm ET
Tandem Diabetes Care Announces Upcoming Conference Participation and Presentations
Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will be attending the following upcoming investor conferences:
Aug 01, 2019 04:05 pm ET
Tandem Diabetes Care Announces Second Quarter 2019 Financial Results and Updated 2019 Financial Guidance
Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today reported its financial results for the quarter ended June 30, 2019 and updated its financial guidance for the year ending December 31, 2019.
Aug 01, 2019 04:02 pm ET
Tandem Diabetes Care Announces No-Cost Software Updates for t:slim X2 Insulin Pump Customers in the United States
Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced it is offering no-cost feature updates for t:slim X2 insulin pump customers in the United States through the end of 2020.
Jul 19, 2019 09:00 am ET
Tandem Diabetes Care to Announce Second Quarter 2019 Financial Results on August 1, 2019
Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its second quarter 2019 results after the financial markets close on Thursday, August 1, 2019. The Company will hold a conference call and simultaneous webcast on the same day at 4:30pm Eastern Time (1:30pm Pacific Time), to discuss its second quarter 2019 financial and operating results.
Jun 20, 2019 09:00 am ET
Tandem Diabetes Care Announces Upcoming Conference Presentation
Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that John Sheridan, president and chief executive officer, will present at the BMO 2019 Prescriptions for Success Healthcare Conference on Tuesday, June 25, 2019 in New York at 1:20pm Eastern Time (10:20am Pacific Time).
Jun 13, 2019 01:31 pm ET
CORRECTING and REPLACING Tandem Diabetes Care Reports Positive Results From Two Studies of the t:slim X2 Insulin Pump With Control-IQ Technology
Fourth paragraph, fourth sentence of release dated June 9, 2019, should read: Time spent below 70 mg/dL was 1.4 percent with Control-IQ technology compared to 1.9 percent in the control group (p
Jun 07, 2019 04:50 pm ET
Tandem Diabetes Care Announces Conference Call Following Data Presentations at the ADA Scientific Sessions
Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will hold a conference call on Sunday, June 9, 2019 at 8:00pm Eastern Time (5:00pm Pacific Time) following data presentations at the 79th Scientific Sessions of the American Diabetes Association on its t:slim X2 with Control-IQ technology system.
May 13, 2019 04:05 pm ET
Tandem Diabetes Care Announces Upcoming Conference Presentations
Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a Company update at the following upcoming investor conferences:
Apr 30, 2019 04:05 pm ET
Tandem Diabetes Care Announces First Quarter 2019 Financial Results and Updated 2019 Financial Guidance
Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today reported its financial results for the quarter ended March 31, 2019 and updated its financial guidance for the year ending December 31, 2019.
Apr 16, 2019 04:15 pm ET
Tandem Diabetes Care to Announce First Quarter 2019 Financial Results on April 30, 2019
Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its first quarter 2019 results after the financial markets close on Tuesday, April 30, 2019. The Company will hold a conference call and simultaneous webcast on the same day at 4:30pm Eastern Time (1:30pm Pacific Time), to discuss its first quarter 2019 financial and operating results.
Mar 07, 2019 04:15 pm ET
Tandem Diabetes Care Approved as Insulin Pump Vendor for ADP in Ontario, Canada
Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that it is now registered as an approved vendor of insulin pumps and supplies under the Assistive Devices Program (ADP) in Ontario, Canada. The t:slim X2 insulin pump features Dexcom G5® Mobile continuous glucose monitoring (CGM) integration,1 making it the only CGM-integrated insulin pump approved in Canada for making daily diabetes treatment decisions without fingersticks.2
Mar 06, 2019 04:41 pm ET
Tandem Diabetes Care Announces Upcoming Conference Presentations
Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that John Sheridan, president and chief executive officer, will present at the following upcoming investor conferences:
Mar 06, 2019 09:15 am ET
Tandem Diabetes Care Announces Plan to Use Remote Software Update Tool in Ongoing Clinical Trial
Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that it intends to use its remote software update tool, the Tandem Device Updater, to resolve a Control-IQ technology software anomaly identified during the ongoing DCLP3 phase of the International Diabetes Closed Loop (IDCL) clinical trial. The Company anticipates that the software update will be available to study sites before the end of March.
Mar 01, 2019 08:20 am ET
Market Trends Toward New Normal in Cypress Semiconductor, OUTFRONT Media, R1 RCM, Graham, CVS Health, and Tandem Diabetes Care — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Cypress Semiconductor Corporation (NASDAQ:CY), OUTFRONT Media Inc. (NYSE:OUT),...
Feb 26, 2019 04:07 pm ET
Tandem Diabetes Care Announces Succession Plan for Chief Executive Officer and Board of Directors
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced a succession plan for its chief executive officer (CEO) and select members of its board of directors.
Feb 26, 2019 04:05 pm ET
Tandem Diabetes Care Reports 2018 Financial Results and 2019 Financial Guidance
Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today reported its financial results for the quarter and year ended December 31, 2018 and financial guidance for the year ending December 31, 2019.
Feb 20, 2019 09:00 am ET
Tandem Diabetes Care Appoints New Senior Vice President to Drive Expansion of Digital Health and Information Technology Initiatives
Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment of Manuel Jaime as its new Senior Vice President, Technology and Digital Health. Jaime will lead all activities related to information technology, data management and security, data analytics, and mobile/connected health solutions.
Feb 14, 2019 06:00 pm ET
t:slim X2 Insulin Pump First to Receive New ACE Pump Classification by FDA
Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that the U.S. Food and Drug Administration (FDA) has classified the t:slim X2™ insulin pump as the first in a new device category called Alternate Controller Enabled Infusion Pumps (ACE pumps). Along with this authorization, the FDA is establishing criteria, called special controls, which outline requirements for assuring the accuracy, reliability, cybersecurity and clinical relevance of ACE pumps, as well as describe the type o
Jan 21, 2019 04:15 pm ET
Tandem Diabetes Care to Announce Fourth Quarter and Full Year 2018 Financial Results on February 26, 2019
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its fourth quarter and full year 2018 results after the financial markets close on Tuesday, February 26, 2019. The Company will hold a conference call and simultaneous webcast on the same day at 4:30pm Eastern Time (1:30pm Pacific Time), to discuss its fourth quarter and full year 2018 financial and operating results.
Jan 03, 2019 04:05 pm ET
Tandem Diabetes Care Announces Appointment of Rebecca Robertson as Board Member
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that Rebecca (Beckie) Robertson was appointed as an independent member of its board of directors.
Dec 27, 2018 08:31 am ET
Thinking about buying stock in Apple Inc., Chesapeake Energy Corp., Cronos Group Inc., Tandem Diabetes Care, or Tesla, Inc.?
NEW YORK, Dec. 27, 2018 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AAPL, CHK, CRON, TNDM, and TSLA....
Dec 03, 2018 07:40 am ET
Investor Expectations to Drive Momentum within Virtu Financial, Fate Therapeutics, Tandem Diabetes Care, Eli Lilly, Griffon, and Coherus BioSciences — Discovering Underlying Factors of Influence
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Virtu Financial, Inc. (NASDAQ:VIRT), Fate Therapeutics, Inc....
Nov 13, 2018 04:30 pm ET
Tandem Diabetes Care to Present at the Credit Suisse Healthcare Conference
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that Kim Blickenstaff, President and Chief Executive Officer and Leigh Vosseller, EVP and Chief Financial Officer, will present at the Credit Suisse 27th Annual Healthcare Conference on Wednesday, November 14, 2018 in Scottsdale, AZ at 12:20pm Eastern Time (9:20am Pacific).
Nov 12, 2018 04:30 pm ET
Tandem Diabetes Care Honored in San Diego 2018 Top Workplaces Awards From San Diego Union-Tribune
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced it has been named a top workplace in San Diego by The San Diego Union-Tribune and awarded a “Future Forward” 2018 Top Workplaces honor.
Nov 08, 2018 04:05 pm ET
Tandem Diabetes Care Announces Upcoming Conference Presentations
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present at the following upcoming investor conferences:
Nov 01, 2018 04:05 pm ET
Tandem Diabetes Care Reports Third Quarter 2018 Financial Results
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today reported its financial results for the quarter ended September 30, 2018.
Oct 24, 2018 09:20 am ET
Analysis: Positioning to Benefit within Spectrum Pharmaceuticals, Carnival, Cadence Design, Tandem Diabetes Care, Rigel Pharmaceuticals, and Regeneron Pharmaceuticals — Research Highlights Growth, Rev
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), Carnival Corporation...
Oct 17, 2018 04:10 pm ET
Tandem Diabetes Care to Announce Third Quarter 2018 Financial Results on November 1, 2018
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps with continuous glucose monitoring integration, plans to release its third quarter 2018 results after the financial markets close on Thursday, November 1, 2018. The Company will hold a conference call and simultaneous webcast on the same day at 5:30pm Eastern Time (2:30pm Pacific Time), to discuss its third quarter 2018 financial and operating results.
Oct 12, 2018 05:00 pm ET
Tandem Diabetes Care Receives Health Canada Approval to Market t:slim X2 Insulin Pump
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps with continuous glucose monitoring (CGM) integration, today announced that it has received a Heath Canada Medical Device License for the t:slim X2™ Insulin Pump. The t:slim X2 Pump features Dexcom G5® Mobile CGM integration,1 making it the only CGM-integrated insulin pump approved in Canada for making daily diabetes treatment decisions without fingersticks.2 The Company plans to l
Sep 25, 2018 09:00 am ET
Tandem Diabetes Care Increases 2018 Sales Guidance and Provides Estimated Third Quarter Sales Results
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps with continuous glucose monitoring integration, today announced that it has increased its 2018 sales guidance to $150 million to $158 million, from $140 million to $148 million, following continued strong domestic sales in the third quarter and the recent launch of the t:slim X2™ Insulin Pump in select international markets. Compared to 2017 sales of approximately $108 million, the revised guidance range represents annual s
Sep 12, 2018 09:00 am ET
Tandem Diabetes Care to Webcast Investor & Analyst Day on September 25, 2018
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps with continuous glucose monitoring integration, today announced it will host an Institutional Investor and Analyst Day from 8:30am to 1:00pm Pacific Time on Tuesday, September 25, 2018 in San Diego, California. The program will include presentations regarding the Company’s longer-term vision, product pipeline, and international expansion. In addition, presentations will be given by clinical and industry experts on the
Aug 29, 2018 04:05 pm ET
Tandem Diabetes Care to Present at the Baird Global Healthcare Conference
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps with continuous glucose monitoring integration, today announced that Kim Blickenstaff, president and CEO, will present a company update at the Baird 2018 Global Healthcare Conference in New York, NY. The presentation will take place on Wednesday, September 5, 2018 at 1:25PM Eastern Time (10:25AM Pacific Time).
Aug 17, 2018 09:00 am ET
Tandem Diabetes Care Announces Commercial Launch of t:slim X2 Insulin Pump with Basal-IQ Technology in the United States
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps with continuous glucose monitoring (CGM) integration, today announced its launch of the t:slim X2™ Insulin Pump with Basal-IQ™ Technology, a predictive low glucose suspend (PLGS) feature designed to help reduce the frequency and duration of low glucose events (hypoglycemia). It is integrated with the Dexcom G6® CGM System, which requires no fingersticks for calibration or diabetes treatment decisions.1,2 The Comp
Aug 08, 2018 04:05 pm ET
Tandem Diabetes Care Announces Full Repayment of Outstanding CRG Debt
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps with continuous glucose monitoring (CGM) integration, today announced that it has fully repaid its term loan made by Capital Royalty Partners II L.P. and its affiliated funds (CRG). The balance of the outstanding debt plus accrued interest owed to CRG was approximately $83.8 million, plus approximately $5.0 million in associated financing fees that became due upon repayment. The interest rate on the term loan was 11.5 perce
Aug 08, 2018 09:00 am ET
Tandem Diabetes Care Announces Publication of PROLOG Study Results in Diabetes Care Journal
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps with continuous glucose monitoring (CGM) integration, today announced the online publication of results from the PROLOG (PLGS for Reduction of Low Glucose) study of the t:slim X2™ Insulin Pump with Basal-IQ™ predictive low glucose suspend technology in the medical journal Diabetes Care. The study demonstrated that the t:slim X2 Pump with Basal-IQ Technology significantly reduced hypoglycemia without rebound hyperglyc
Aug 07, 2018 04:05 pm ET
Tandem Diabetes Care Announces Closing of $115 Million Underwritten Public Offering of Common Stock
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), (“Tandem”) a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced the closing of its previously announced underwritten public offering of 3,508,770 shares of common stock at a price to the public of $28.50 per share. In addition, the underwriters fully exercised an option to purchase 526,315 additional shares of common stock at the public offering price. All of the shares in the offering were offered by Tandem, with gro
Aug 03, 2018 09:00 am ET
Tandem Diabetes Care Announces Pricing of $100 Million Public Offering of Common Stock
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM) (“Tandem”), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced the pricing of an underwritten public offering of 3,508,770 shares of its common stock at a price to the public of $28.50 per share. The gross proceeds to Tandem from this offering are expected to be approximately $100.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Tandem. In addition, Tandem has g
Aug 02, 2018 04:01 pm ET
Tandem Diabetes Care Announces Proposed Underwritten Public Offering of Common Stock
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM) (“Tandem”), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced that it has commenced a proposed underwritten public offering of its common stock. All of the shares to be sold in the offering will be offered by Tandem. In addition, Tandem expects to grant to the underwriters a 30-day option to purchase up to 15 percent of the offering in additional common stock. The number of shares to be offered and the price per share have not
Jul 30, 2018 04:05 pm ET
Tandem Diabetes Care Reports Second Quarter 2018 Financial Results
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pump available in the United States, today reported its financial results for the quarter ended June 30, 2018.
Jul 16, 2018 04:05 pm ET
Tandem Diabetes Care Schedules Second Quarter 2018 Earnings Press Release and Conference Call
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, plans to release its second quarter 2018 results after the financial markets close on Monday, July 30, 2018. The Company will hold a conference call and simultaneous webcast on the same day at 4:30pm Eastern Time (1:30pm Pacific Time), to discuss its second quarter 2018 financial and operating results.
Jun 21, 2018 04:05 pm ET
Tandem Diabetes Care Announces FDA Approval of t:slim X2 Insulin Pump with Basal-IQ Technology
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced U.S. Food and Drug Administration (FDA) approval of the t:slim X2™ Insulin Pump with Basal-IQ™ technology, a predictive low glucose suspend (PLGS) feature designed to help reduce the frequency and duration of low glucose events (hypoglycemia). This is the first automated insulin delivery system approved for use by children as young as 6 years old, and the first insulin pump de
Jun 12, 2018 07:30 am ET
Report: Developing Opportunities within ConocoPhillips, Teleflex, Enterprise Products Partners, Tandem Diabetes Care, J.B. Hunt Transport Services, and Ascena Retail Group — Future Expectations, Proje
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ConocoPhillips (NYSE:COP), Teleflex Incorporated (NYSE:TFX), Enterprise...
Jun 01, 2018 09:00 am ET
Faruqi & Faruqi, LLP is Investigating Tandem Diabetes Care, Inc. (TNDM) on Behalf of its Shareholders
NEW YORK, June 1, 2018 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities law violations at Tandem Diabetes Care, Inc. ("Tandem" or the "Company") (NASDAQ: TNDM)....
May 09, 2018 04:15 pm ET
Tandem Diabetes Care to Present at the Bank of America Merrill Lynch 2018 Healthcare Conference
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced that Kim Blickenstaff, president and CEO, will present a company update at the Bank of America Merrill Lynch 2018 Healthcare Conference, which will be held at the Encore at the Wynn Hotel in Las Vegas, Nevada. The presentation will take place on Tuesday, May 15, 2018 at 12:35 PM Eastern Time (9:35 AM Pacific Time).
May 01, 2018 04:05 pm ET
Tandem Diabetes Care to Present at the Deutsche Bank 43rd Annual Health Care Conference
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced that Kim Blickenstaff, president and CEO, will present a company update at the Deutsche Bank 43rd Annual Health Care Conference in Boston, MA. The presentation will take place on Tuesday, May 8, 2018 at 10:40 AM Eastern Time (7:40 AM Pacific Time).
Apr 30, 2018 08:30 am ET
Tandem Diabetes Care Receives CE Mark for t:slim X2 Insulin Pump
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps, today announced receipt of CE mark approval for the t:slim X2™ Insulin Pump with Dexcom G5® Mobile continuous glucose monitoring (CGM) integration1. The Company plans to begin commercial sales of the pump in select international markets beginning in the second half of 2018. The Company has been commercializing its touchscreen insulin pumps in the United States since 2012, and received U.S. Food and Drug Administ
Apr 26, 2018 04:03 pm ET
Tandem Diabetes Care Reports First Quarter 2018 Financial Results
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today reported its financial results for the quarter ended March 31, 2018.
Apr 23, 2018 04:30 pm ET
Tandem Diabetes Care Announces Agreements for Distribution of Insulin Pump Products in Australia and New Zealand
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced that it has entered into distribution agreements with Australasian Medical & Scientific Ltd (AMSL) and New Zealand Medical & Scientific Ltd (NZMS) to commercialize Tandem’s t:slim X2™ Insulin Pump in Australia and New Zealand, respectively.
Apr 18, 2018 04:30 pm ET
Tandem Diabetes Care Schedules First Quarter 2018 Earnings Press Release and Conference Call
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, plans to release its first quarter 2018 results after the financial markets close on Thursday, April 26, 2018. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time), to discuss its first quarter 2018 financial and operating results.
Apr 10, 2018 08:30 am ET
Tandem Diabetes Care Announces Preliminary First Quarter 2018 Results
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today reported select, unaudited and preliminary results for the quarter ended March 31, 2018.
Apr 09, 2018 09:00 am ET
Tandem Diabetes Care and Movi SpA Announce Agreement for Distribution of Insulin Pump Products in Italy
Tandem Diabetes Care®, Inc. (NASDAQ: tndm), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced that it has entered into a distribution agreement with Movi SpA to commercialize Tandem’s t:slim X2™ Insulin Pump in Italy.
Mar 07, 2018 04:30 pm ET
Tandem Diabetes Care Announces Upcoming Conference Presentations
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced that Kim Blickenstaff, president and CEO, will present a company update at the following upcoming investor conferences:
Mar 01, 2018 04:00 pm ET
Tandem Diabetes Care Announces 2017 Financial Results
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today reported its financial results for the year and quarter ended December 31, 2017 and financial guidance for the year ending December 31, 2018.
Feb 20, 2018 04:30 pm ET
Tandem Diabetes Care Applies for Health Canada Medical Device License
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps, today announced its submission of a medical device license application to Health Canada to market its t:slim X2™ Insulin Pump with Dexcom G5® Mobile continuous glucose monitoring (CGM) integration1. The Company plans to launch the pump in Canada in the second half of 2018, subject to regulatory approvals.
Feb 16, 2018 08:20 am ET
Report: Exploring Fundamental Drivers Behind Life Storage, Suburban Propane Partners, DCT Industrial Trust, United Continental, Tandem Diabetes Care, and Crown Castle International — New Horizons, Eme
NEW YORK, Feb. 16, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Life Storage, Inc. (NYSE:LSI), Suburban Propane...
Feb 15, 2018 04:30 pm ET
Tandem Diabetes Care and Rubin Medical Announce Agreement for Distribution of Insulin Pump Products in Scandinavia
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced that it has entered into a distribution agreement with Rubin Medical to commercialize Tandem’s t:slim X2™ Insulin Pump, insulin cartridges, and t:lock™ family of Infusion Sets in Sweden, Norway and Denmark.
Feb 15, 2018 09:20 am ET
Reduced Time in Hypoglycemia Demonstrated in Tandem Diabetes Care’s Pivotal Trial for the t:slim X2 Insulin Pump with Predictive Low Glucose Suspend Feature; Data to be Presented at ATTD 2018 Conferen
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced positive results from a pivotal study of the t:slim X2™ Insulin Pump with Basal-IQ technology, a predictive low glucose suspend (PLGS) feature. Data showed that the system achieved the primary outcome of reducing time spent in hypoglycemia compared to sensor-augmented pump therapy alone. Details from the study are being presented today at the 11th Annual Conference
Feb 14, 2018 04:15 pm ET
Tandem Diabetes Care Schedules Fourth Quarter and Full Year 2017 Earnings Press Release and Conference Call
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, plans to release its fourth quarter and full year 2017 results after the financial markets close on Thursday, March 1, 2018. The Company will hold a conference call and simultaneous webcast on the same day at 4:30pm Eastern Time (1:30pm Pacific Time), to discuss its fourth quarter and full year 2017 financial and operating results.
Feb 13, 2018 04:10 pm ET
Tandem Diabetes Care Announces Closing of $69 Million Underwritten Public Offering of Common Stock
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced the closing of its previously announced underwritten public offering of 30 million shares of common stock at a price to the public of $2.00 per share. In addition, the underwriters fully exercised an option to purchase 4.5 million additional shares of common stock at the public offering price. All of the shares in the offering were offered by Tandem, with gross proc
Feb 09, 2018 08:30 am ET
Tandem Diabetes Care Announces Pricing of $60 Million Underwritten Public Offering of Common Stock
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced the pricing of an underwritten public offering of 30 million shares of its common stock at a price to the public of $2.00 per share. The gross proceeds to Tandem from this offering are expected to be $60 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Tandem. In addition, Tandem has granted the underwriters a 30
Jan 09, 2018 04:15 pm ET
Tandem Diabetes Care Announces Preliminary 2017 Results and Provides 2018 Guidance
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today reported select, unaudited and preliminary results for the year and quarter ended December 31, 2017.
Jan 08, 2018 09:15 am ET
Tandem Diabetes Care Reports Successful Completion of First Pilot Study Using t:slim X2 Insulin Pump with TypeZero Hybrid Closed Loop Technology and Dexcom G6 Integration; Confirms IDCL Multi-site Stu
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today reported the successful completion of the first pilot study using a hybrid closed loop system featuring its t:slim X2™ Insulin Pump with embedded algorithms from TypeZero Technologies and integration with Dexcom® G6 Continuous Glucose Monitoring (CGM). This pilot study was the first of three in the National Institute of Health (NIH)-funded International Diabetes Closed Loop (IDCL) Trial
Jan 03, 2018 09:00 am ET
Tandem Diabetes Care Commences Full Manufacturing Operations at New San Diego Facility
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced the commencement of full manufacturing operations at its new facility located on Barnes Canyon Road in San Diego. In support of the Company’s growing operations, the 50,000-square-foot Barnes Canyon facility doubles its previous manufacturing capacity for both insulin pumps and cartridges and expands warehousing for additional infusion set supplies related to the launch
Dec 14, 2017 09:00 am ET
Tandem Diabetes Care Announces Issuance of Patent Related to Automated Insulin Delivery Technology
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced the issuance of U.S. Patent No. 9,833,177 titled “Insulin Pump Based Expert System.” This patent is part of the portfolio of intellectual property acquired by the Company from Smiths Medical ASD, Inc. in 2013. It refers to a pump system that suspends, among other operations, the delivery of insulin if a user’s sensor glucose data reaches or falls below an accepta
Dec 07, 2017 04:30 pm ET
Tandem Diabetes Care Announces Retirement of CFO and Successor Appointment
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM) today announced the retirement of its executive vice president and chief financial officer (CFO), John Cajigas, effective December 31, 2017. Leigh Vosseller, who is currently serving at Tandem’s senior vice president of finance, will be promoted to CFO effective January 1, 2018.
Dec 04, 2017 07:50 am ET
Report: Developing Opportunities within United Continental, Tandem Diabetes Care, Cavium, Life Storage, Suburban Propane Partners, and DCT Industrial Trust — Future Expectations, Projections Moving in
NEW YORK, Dec. 04, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of United Continental Holdings, Inc. (NYSE:UAL), Tandem...
Nov 16, 2017 04:30 pm ET
Tandem Diabetes Care to Present at the 29th Annual Piper Jaffray Healthcare Conference
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced that Kim Blickenstaff, president and CEO, will present a company update at the 29th Annual Piper Jaffray Healthcare Conference in New York, NY. The presentation will take place on Wednesday, November 29, 2017 at 11:30AM Eastern Time (8:30AM Pacific Time).
Nov 07, 2017 04:30 pm ET
Tandem Diabetes Care to Present at the Stifel 2017 Healthcare Conference
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced that Kim Blickenstaff, president and CEO, will present a company update at the Stifel 2017 Healthcare Conference in New York, NY. The presentation will take place on Tuesday, November 14, 2017 at 2:00PM Eastern Time (11:00AM Pacific Time).
Nov 02, 2017 04:30 pm ET
Human Factors Research Presented at DTM 2017 Demonstrates Ease of Use and Effectiveness of Computer-Based Training for Touchscreen Insulin Pump with Automated Insulin Delivery Feature
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today presented results from a Human Factors study conducted to validate the safety of the user interface of a predictive low glucose suspend (PLGS) feature as part of the t:slim X2™ Insulin Pump. The study included users ages 6 and up (N=53), with and without experience using an insulin pump or continuous glucose monitoring (CGM). The study demonstrated a 99 percent success rate among study
Nov 02, 2017 08:15 am ET
Analysis: Positioning to Benefit within Tandem Diabetes Care, CASI Pharmaceuticals, SAExploration, Roka Bioscience, VirnetX, and PhaseRx – Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, Nov. 02, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Tandem Diabetes Care, Inc. (NASDAQ:TNDM), CASI...
Oct 26, 2017 04:05 pm ET
Tandem Diabetes Care Reports Third Quarter 2017 Financial Results
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today reported its financial results for the quarter ended September 30, 2017.
Oct 24, 2017 04:30 pm ET
Tandem Diabetes Care to Provide All t:slim X2 Insulin Pump Features Approved in 2018 to Users at No Cost and Expands Existing Dexcom Welcome Offer for Animas Customers
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced that it will make any new features approved for the t:slim X2™ Insulin Pump by the U.S. Food and Drug Administration (FDA) in 2018 available to all in-warranty users at no cost through the Tandem Device Updater.1 Tandem and continuous glucose monitoring partner, Dexcom, Inc., also announced the extension of their existing joint welcome program for Animas customers
Oct 16, 2017 04:30 pm ET
Tandem Diabetes Care Schedules Third Quarter 2017 Earnings Press Release and Conference Call
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, plans to release its third quarter 2017 results after the financial markets close on Thursday, October 26, 2017. The Company will hold a conference call and simultaneous webcast on the same day at 4:30pm Eastern Time (1:30pm Pacific Time), to discuss its third quarter 2017 financial and operating results.
Oct 13, 2017 09:10 am ET
Tandem Diabetes Care Announces Pricing of $16.2 Million Underwritten Public Offering of Common Stock and Warrants
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced the pricing of an underwritten public offering of (i) 4,630,000 shares of its common stock, (ii) Series A warrants to purchase 4,630,000 shares of its common stock and (iii) Series B warrants to purchase 4,630,000 shares of its common stock, for gross proceeds of approximately $16.2 million, at a public offering price of $3.50 per share and accompanying warrants. The Series A
Oct 12, 2017 04:01 pm ET
Tandem Diabetes Care Announces Proposed Underwritten Public Offering of Common Stock, Series A Warrants and Series B Warrants
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced that it is proposing to offer and sell shares of its common stock, Series A warrants and Series B warrants to purchase shares of its common stock in an underwritten public offering. All of the shares of common stock and warrants to be sold in the offering are being offered by Tandem. The offering is subject to market conditions and there can be no assurance as to whether or wh
Oct 09, 2017 09:00 am ET
Tandem Diabetes Care Announces Approval of Reverse Stock Split
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM) previously announced that a proposal was approved at its Special Meeting of Stockholders, held September 7, 2017, authorizing its Board of Directors to amend the Company's certificate of incorporation to effect a reverse stock split of the Company’s issued and outstanding shares of common stock at a ratio not less than 1-for-8 and not greater than 1-for-12, with the exact ratio to be set within that range by Tandem’s Board of Directors. The number of authorized shares of common stock would remain at 100